Literature DB >> 17662659

Syk kinase as a treatment target for therapy in autoimmune diseases.

Vasileios C Kyttaris1, George C Tsokos.   

Abstract

Spleen tyrosine kinase (Syk) associates with a variety of immunoreceptors in myeloid and lymphoid cells. Syk initiates intracellular signaling once the receptor is engaged by its ligand. Blocking Syk may prove beneficial in interrupting the propagation of the abnormal immune response in both autoimmune and allergic diseases.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17662659      PMCID： PMC1986716          DOI： 10.1016/j.clim.2007.06.005

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  12 in total

Review 1.  Imatinib mesylate--a new oral targeted therapy.

Authors:  David G Savage; Karen H Antman
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

2.  Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus.

Authors:  E J Enyedy; M P Nambiar; S N Liossis; G Dennis; G M Kammer; G C Tsokos
Journal:  Arthritis Rheum       Date:  2001-05

Review 3.  Src and Syk kinases: key regulators of phagocytic cell activation.

Authors:  Giorgio Berton; Attila Mócsai; Clifford A Lowell
Journal:  Trends Immunol       Date:  2005-04       Impact factor: 16.687

Review 4.  Role of ITAM-containing adapter proteins and their receptors in the immune system and bone.

Authors:  Mary Beth Humphrey; Lewis L Lanier; Mary C Nakamura
Journal:  Immunol Rev       Date:  2005-12       Impact factor: 12.988

5.  Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Authors:  Polly R Pine; Betty Chang; Nathan Schoettler; Mona L Banquerigo; Su Wang; Angela Lau; Feifei Zhao; Elliott B Grossbard; Donald G Payan; Ernest Brahn
Journal:  Clin Immunol       Date:  2007-05-29       Impact factor: 3.969

6.  Progressive loss of Syk and abnormal proliferation in breast cancer cells.

Authors:  Maria Moroni; Viatcheslav Soldatenkov; Li Zhang; Ying Zhang; Gerald Stoica; Edmund Gehan; Banafsheh Rashidi; Baljit Singh; Metin Ozdemirli; Susette C Mueller
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

7.  The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase.

Authors:  Attila Mócsai; Mary Beth Humphrey; Jessica A G Van Ziffle; Yongmei Hu; Andrew Burghardt; Steven C Spusta; Sharmila Majumdar; Lewis L Lanier; Clifford A Lowell; Mary C Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

8.  Protein-tyrosine kinase p72syk in high affinity IgE receptor signaling. Identification as a component of pp72 and association with the receptor gamma chain after receptor aggregation.

Authors:  M Benhamou; N J Ryba; H Kihara; H Nishikata; R P Siraganian
Journal:  J Biol Chem       Date:  1993-11-05       Impact factor: 5.157

9.  Human spleen tyrosine kinase p72Syk associates with the Src-family kinase p53/56Lyn and a 120-kDa phosphoprotein.

Authors:  S P Sidorenko; C L Law; K A Chandran; E A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

10.  Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.

Authors:  Lei Wang; Lindsay Duke; Peter S Zhang; Ralph B Arlinghaus; W Fraser Symmans; Aysegul Sahin; Richard Mendez; Jia Le Dai
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701
View more
  12 in total

1.  Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion.

Authors:  Omer Nuri Pamuk; Peter H Lapchak; Poonam Rani; Polly Pine; Jurandir J Dalle Lucca; George C Tsokos
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-03       Impact factor: 4.052

Review 2.  Novel treatments for immune thrombocytopenia.

Authors:  Andrew Shih; Ishac Nazi; John G Kelton; Donald M Arnold
Journal:  Presse Med       Date:  2014-03-20       Impact factor: 1.228

Review 3.  Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.

Authors:  David L Scott
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

Authors:  Guo-Min Deng; Lena Liu; Frances Rena Bahjat; Polly R Pine; George C Tsokos
Journal:  Arthritis Rheum       Date:  2010-07

Review 5.  Neutrophils: game changers in glomerulonephritis?

Authors:  Tanya N Mayadas; Florencia Rosetti; Thomas Ernandez; Sanjeev Sethi
Journal:  Trends Mol Med       Date:  2010-07-29       Impact factor: 11.951

6.  Development of a HTRF kinase assay for determination of Syk activity.

Authors:  Christopher Harbert; Jeannette Marshall; Sharon Soh; Krista Steger
Journal:  Curr Chem Genomics       Date:  2008-02-25

Review 7.  Small molecules in the treatment of systemic lupus erythematosus.

Authors:  Anastasia Markopoulou; Vasileios C Kyttaris
Journal:  Clin Immunol       Date:  2012-10-02       Impact factor: 3.969

8.  Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.

Authors:  Sumit Kunwar; Ashok Raj Devkota; Dipesh K C Ghimire
Journal:  Rheumatol Int       Date:  2016-04-25       Impact factor: 2.631

Review 9.  Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury.

Authors:  Tanya N Mayadas; George C Tsokos; Naotake Tsuboi
Journal:  Circulation       Date:  2009-11-17       Impact factor: 29.690

Review 10.  Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases.

Authors:  Omer N Pamuk; George C Tsokos
Journal:  Arthritis Res Ther       Date:  2010-12-17       Impact factor: 5.156
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.